Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.

Authors :: Packer M
Source :: Circulation [Circulation] 2019 Aug 06; Vol. 140 (6), pp. 443-445. Date of Electronic Publication: 2019 Aug 05.
Publication Year :: 2019

Subjects :: Benzhydryl Compounds pharmacology
Benzhydryl Compounds therapeutic use
Blood Volume drug effects
Death, Sudden, Cardiac etiology
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 physiopathology
Diabetic Cardiomyopathies complications
Diabetic Cardiomyopathies physiopathology
Diuretics therapeutic use
Glucose metabolism
Glucosides pharmacology
Glucosides therapeutic use
Heart Failure etiology
Heart Failure physiopathology
Hospitalization statistics & numerical data
Humans
Hypoglycemic Agents therapeutic use
Kidney Tubules, Proximal drug effects
Kidney Tubules, Proximal metabolism
Multicenter Studies as Topic
Myocardial Infarction etiology
Myocardial Infarction prevention & control
Natriuresis drug effects
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 physiology
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Stroke etiology
Stroke prevention & control
Stroke Volume drug effects
Death, Sudden, Cardiac prevention & control
Diabetes Mellitus, Type 2 drug therapy
Heart Failure drug therapy
Hypoglycemic Agents pharmacology
Sodium-Glucose Transporter 2 Inhibitors pharmacology
Sodium-Hydrogen Exchanger 1 antagonists & inhibitors

Full Text Access

Tools